Abstract: The specification describes a zirconia support comprising ?95 wt % ZrO2, wherein: the support has a crush strength of 20 to 140 N; the support has a total pore volume of 0.10 to 0.40 mL/g when measured by N2 physisorption; the support has an acid site density of 15 to 30 ?LNH3/m2; and the support has a basic site density of 0.006 to 0.015 wt %/m2 as measured by the MBOH test. Also described is a method for producing a zirconia supporting starting from zirconia or zirconium hydroxide as raw materials.

Abstract: The specification describes a catalyst for the hydrodeoxygenation of alcohols, comprising: 0.1 to 1.5 wt % palladium; 1.0 to 5.0 wt % molybdenum; and 0.05 to 0.5 wt % tin; on a zirconia support. Also described is a method for manufacturing the catalyst and a hydrodeoxygenation process using the catalyst.

Abstract: The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.

Abstract: Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.

Abstract: Anti-Epstein Barr Virus (EBV) vaccines are described herein. The EBV vaccine antigens are linked to a multimerization domain, for example, presented on a circular tandem repeat protein (cTRP) scaffold or linked to a C4b multimerization domain. The vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.

Abstract: Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.

Abstract: The disclosure provides antibodies, antibody fragments, and antibody derivatives that bind to the viral envelope spike protein (S2P) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and related compositions, and methods. In some embodiments, the antibodies, antibody fragments, and antibody derivatives bind to an epitope of the receptor binding domain (RBD) of SARS-CoV-2.

Abstract: Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.

Abstract: Anti-Epstein Barr Virus (EBV) antibodies and vaccines are described herein. The antibodies and vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.

Abstract: Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.

Abstract: Anti-Epstein Barr Virus (EBV) antibodies and vaccines are described herein. The antibodies and vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.

Abstract: Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.

Abstract: Multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins are multimerized Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp 120) and can used as an HIV vaccine.

Abstract: Devices and methods for measuring roller chain wear are provided. A roller chain wear gauge may include an elongated structure configured to be inserted into a gap between two roller links of a chain joined by a pin link of the chain, the chain having an associated chain size. The elongated structure may include a first side surface, a second side surface, a length extending along a longitudinal axis of the elongated structure, and a plurality of widths located along the length and defined by and between the first and second side surfaces. The first side surface may extend at an angle relative to the longitudinal axis such that the plurality of widths continuously tapers over the length. The plurality of widths may be calibrated against a reference chain representative of the associated chain size.

Abstract: Multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins are multimerized Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.

Abstract: Devices and methods for measuring roller chain wear are provided. A roller chain wear gauge may include an elongated structure configured to be inserted into a gap between two roller links of a chain joined by a pin link of the chain, the chain having an associated chain size. The elongated structure may include a first side surface, a second side surface, a length extending along a longitudinal axis of the elongated structure, and a plurality of widths located along the length and defined by and between the first and second side surfaces. The first side surface may extend at an angle relative to the longitudinal axis such that the plurality of widths continuously tapers over the length. The plurality of widths may be calibrated against a reference chain representative of the associated chain size.